Aller au contenu
Retour à la recherche

NCT07102264Recrutement en cours

Safety & Feasibility of Ultrasound-assisted Non-invasive Measurement of Compressibility of the Thyroid Gland in Patients Scheduled for Surgical Removal

Résumé

The thyroid gland plays an important role in hormone regulation however, it is often prone to nodules. This is common with nodules being found in up to 68% of people in a neck ultrasound, with likelihood increasing with age. However, only about 1 in 20 nodules turns out to be cancerous. Diagnosis of thyroid nodules starts with ultrasonic assessment, where specific features have been identified to estimate the risk of malignancy. If further examination is recommended, Fine Needle Aspiration (FNA) is performed. A needle is inserted into the nodule and the obtained subset of cells are then classified into 6 categories (Bethesda score) after examination under the microscope. While some Bethesda scores provide very accurate malignancy predictions, others like category 4, are unspecific, with risk of malignancy ranging from 25 to 40%. For these patients, about 75% are operated on even though they are not prospectively diagnosed. Soft tissue has certain physical properties, including its compressibility, which could be quantified by measuring the pressure required to deform it. It has been found that cancerous tissue is often harder than the surrounding healthy tissue. Compremium, a Swiss company which has its headquarters in Muri bei Bern, has developed a device that can be used to measure the compressibility of tissue, similarly to palpation but providing a quantitative assessment. The present study aims to investigate the feasibility and preliminary efficacy of this new technology to predict if thyroid nodules of patients scheduled for surgical removal based on FNA analysis are malignant or not.

Critères d'inclusion

• Patients older than 18 years • Patients with a thyroid node • Patients with a Bethesda IV cytopathological diagnosis of this node • Informed consent documented by signature

Critères d'exclusion

• Non-intact skin at the measurement site • BMI\>35kg/m2 • Patients unable to provide informed consent • Pregnant or breastfeeding women

Contacts

Les coordonnées de l'équipe de l'essai s'affichent sur demande.

Voir la fiche officielle de l'essai
Statut
Recrutement en cours
Phase
Sans phase (N/A)
Type d'étude
Interventionnelle
Pays
Suisse
Promoteur
Insel Gruppe AG, University Hospital Bern(Autre)
N° de protocole
CPMX-Thyr
Pathologies
Thyroid Nodule (Diagnosis)
Interventions
Dispositif

Traitements évalués

  • CPMX1

Lieux · 1

  • Bern, SuisseDepartment of Oto-Rhino-Laryngology, Head and Neck surgery Inselspital, Bern University Hospital and University of BernRecrute dans ce centre

Au total, dans le monde, le seul centre listé au registre recrute.

Statut par centre selon le registre ClinicalTrials.gov (dernière mise à jour publiée : 19 août 2025).

Ce statut peut avoir changé et ne dit rien de votre éligibilité : avant toute démarche, vérifiez avec votre oncologue ou le centre.

Voir aussi

Autres versions

Ces résultats sont indicatifs et ne remplacent pas un avis médical — à discuter avec votre médecin.